More than 100,000 contacts have passed through the program since November 2013 SEATTLE , July 15, 2014 /PRNewswire/ -- Zillow, Inc. (NASDAQ: Z) , the leading real estate information marketplace, today announced that Zillow® Tech Connect has surpassed 25 partners.
MyNewPlace to get Zillow's multifamily listing inventory; Zillow to offer RealPage's real-time price, availability and Live Agent Service to rental customers
SEATTLE , July 21, 2014 /PRNewswire/ -- Zillow, Inc. (NASDAQ: Z) , the leading real estate and home-related marketplace, today announced a new partnership with RealPage (NASDAQ: RP) , a leading provider of on-demand property management software, to help connect multifamily companies with new residents.
By Michael Calia
Zillow Inc. has reached a deal to buy rival Trulia Inc., an expected agreement that brings together two of the biggest names in the fast-growing market for online real-estate information.
SEATTLE, July 25, 2014 (GLOBE NEWSWIRE) -- Zillow, Inc. (Nasdaq:Z) , the leading real estate information marketplace, today announced that Zillow® executives will participate in the following August investor conferences:
About Zillow, Inc.
Zillow, Inc. (Nasdaq:Z) operates the leading real estate and home-related marketplaces on mobile and the Web, with a complementary portfolio of brands and products that help people find vital information about homes, and connect with the best local professionals.
Zillow, Inc. (NASDAQ: Z) and Trulia, Inc. (NYSE: TRLA) announced today
that they each received a Request for Additional Information, or a
"second request," from the United States Federal Trade Commission (FTC)
in connection with the FTC's review of Zillow’s proposed acquisition of
Trulia under the Hart-Scott-Rodino Antitrust Improvements Act of 1976
(the Act). This second request from the FTC is a standard part of the
full regulatory process.
NEW YORK (MarketWatch) -- Shares of real estate websites Zillow Inc. (ZILLOW.XX) and Trulia Inc. (TRLA) surged in afternoon trade Thursday, after Bloomberg said Zillow is seeking to buy Trulia, citing people with knowledge of the matter.
SAN FRANCISCO (MarketWatch) -- Online real-estate brokers were in the tech spotlight Monday, as Zillow Inc. (ZILLOW.XX) said it would acquire rival Trulia Inc. (TRLA) for $3.5 billion in an all-stock deal.
Zilog, Inc., a wholly-owned subsidiary of IXYS Corporation (NASDAQ:IXYS)
and a pioneer supplier of microcontrollers (MCUs) providing solutions
for the industrial, telecommunication, automotive and consumer markets,
introduces a Z8F2480-based AC power monitor with an eZ80F91 Webserver,
expanding its portfolio of reference designs and fast time-to-market
- Net Sales of $1.18 billion represent an increase of 1.2% reported over the prior year period (an increase of 0.9% constant currency) - Diluted EPS for the second quarter were $1.03 reported, an increase of 15.7% over the prior year period, and $1.49 adjusted, an increase of 4.2% over the prior year period
- Company updates sales and earnings guidance for full-year 2014 WARSAW, Ind.
SALT LAKE CITY , July 28, 2014 /PRNewswire/ -- Zions Bancorporation (NASDAQ: ZION) ("Zions") announced today that it has commenced a public offering of $525 million of its common stock pursuant to a prospectus supplement dated July 28, 2014 to its prospectus dated April 21 , 2014.
SALT LAKE CITY , July 21, 2014 /PRNewswire/ -- Zions Bancorporation (NASDAQ: ZION) ("Zions" or "the Company") today reported second quarter net earnings applicable to common shareholders of $104.5 million , or $0.56 per diluted common share, compared to $76.2 million , or $0.41 per diluted share for the first quarter of 2014, and $55.4 million , or $0.30 per diluted share for the second quarter of 2013.
SALT LAKE CITY , July 1, 2014 /PRNewswire/ -- Zions Bancorporation (Nasdaq: ZION) announced today that it will report its second quarter 2014 earnings results after the NASDAQ close on Monday, July 21, 2014 .
Expansion of synthetic immuno-oncology programs to include chimeric antigen receptor T-cell (CAR-T) therapy Increased applications of RheoSwitch ® platform and its unique capabilities into targeted cellular oncology products Phase I trial utilizing Ad-RTS-IL-12 in Glioblastoma Multiforme expected to launch in 2H2014
BOSTON and GERMANTOWN, Md., July 22, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. ("ZIOPHARM") (Nasdaq:ZIOP) , a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the expansion of synthetic immuno-oncology programs in conjunction with Intrexon Corporation (NYSE:XON) to include chimeric antigen receptor T-cell (CAR-T) therapy.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.